section 8
on 26 Jan 2024
Last Applicant/ Owned by
701 CENTRE AVENUE
FORT COLLINS
CO
80526
Serial Number
85515924 filed on 13th Jan 2012
Registration Number
4369447 registered on 16th Jul 2013
Correspondent Address
Kevin C. Parks
Filing Basis
1. intent to use
2. use application currently
Disclaimer
"THERAPEUTICS"
"THERAPEUTICS" The wording "CLARUS" has no meaning in a foreign language. Color is not claimed as a feature of the mark. Pharmaceutical preparations for androgen therapies for men and women deficient in endogenous androgens, testosterone The mark consists of the wording "Clarus Therapeutics" with the stylized design of a testosterone molecule consisting of 3 cyclohexane rings and 1 cyclopentanRead More
Pharmaceutical preparations for androgen therapies for men and women deficient in endogenous androgens, testosterone
03rd May 2013
03rd May 2013
No 85515924
No Service/Collective Mark
No 274504
No
No
No
No
No
No
No
No
24.17.02 -
Male and female biological symbols
26.15.13 -
More than one polygon
26.15.16 -
Polygons touching or intersecting
26.15.21 -
Polygons that are completely or partially shaded
The mark consists of the wording "Clarus Therapeutics" with the stylized design of a testosterone molecule consisting of 3 cyclohexane rings and 1 cyclopentane ring. An arrow representing the "male symbol" arises from the side of the cyclopentane ring.
| Status Date | Action Taken |
|---|---|
| 26th Jan 2024 | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 |
| 01st Feb 2023 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| 16th Jul 2022 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED |
| 13th Apr 2019 | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
| 13th Apr 2019 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED |
| 12th Apr 2019 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| 11th Mar 2019 | TEAS SECTION 8 & 15 RECEIVED |
| 16th Jul 2018 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| 16th Jul 2013 | REGISTERED-PRINCIPAL REGISTER |
| 11th Jun 2013 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
